<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348438</url>
  </required_header>
  <id_info>
    <org_study_id>ENG CIP-001</org_study_id>
    <nct_id>NCT01348438</nct_id>
  </id_info>
  <brief_title>Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial</brief_title>
  <official_title>Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and clinical performance of the Engager
      Transcatheter Aortic Valve Implantation System in patients with severe aortic valve stenosis
      who are at high risk for surgical valve replacement.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 Days</time_frame>
    <description>All-cause mortality within 30 days post-implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) free survival at 30 days and 6 months post implantation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device and procedure related Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Engager Transcatheter Aortic Valve Implantation System</intervention_name>
    <description>Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe aortic stenosis defined as one or more of the following by Doppler
             echocardiography: mean gradient &gt; 40 mmHg; max velocity &gt; 4m/s; aortic valve area ≤
             0.8 cm2.

          2. Symptoms related to aortic valve disease, and NYHA Functional Class II or greater.

          3. Logistic EuroSCORE predicted risk for mortality of ≥20%, or comorbidity judged by the
             investigator to pose an absolute or relative contraindication for conventional aortic
             valve replacement.

          4. Patient is indicated for aortic valve implantation with a biological prosthesis
             (tissue valve) in accordance with the 2007 European Society of Cardiology (ESC)
             Guidelines for management of valvular heart disease.

          5. Age ≥ 18 years.

          6. Echocardiographically determined aortic annulus diameter of ≥19 mm and ≤ 26 mm in a
             long-axis view.

        Exclusion Criteria:

          1. Congenital unicuspid or bicuspid aortic valve.

          2. Severe eccentricity of calcification, defined as calcium deposits larger than 6mm in
             diameter.

          3. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.

          4. Left ventricular ejection fraction &lt; 25%, as determined by contrast ventriculography,
             or echocardiography or radionuclide angiography if contrast ventriculography not
             available

          5. Hypertrophic obstructive cardiomyopathy.

          6. Patients with life expectancy less than 12 months due to an underlying non-cardiac
             comorbid disease.

          7. Known hypersensitivity or contraindication that cannot be adequately controlled with
             pre-medication to any study medication or material, such as contrast medium or
             Nitinol.

          8. Sepsis or acute endocarditis.

          9. Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding
             diathesis, or coagulopathy.

         10. Renal insufficiency assessed by creatinine &gt; 2.5 mg/dl and/or end stage renal disease
             requiring chronic dialysis.

         11. Active peptic ulcer or GI bleeding within 3 months from the planned index procedure.

         12. Untreated clinically significant coronary artery disease requiring revascularization.

         13. Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring
             inotropic support or mechanical heart assistance.

         14. Significant aortic disease, including abdominal and thoracic aortic aneurysm, defined
             as maximal luminal diameter of 5 cm or greater.

         15. Need for emergency surgery, cardiac or non-cardiac.

         16. History of myocardial infarction in the last 6 weeks.

         17. History of TIA or CVA in the last 6 months.

         18. Therapeutic invasive cardiac procedure, with the exception of aortic balloon
             valvuloplasty, performed within 30 days of the planned date of valve implantation, or
             6 months in the case of drug-eluting stents.

         19. Pre-existing prosthetic heart valve or prosthetic ring in any position.

         20. Mitral regurgitation greater than 2+ by angiography or moderate by echocardiography.

         21. Patient refuses a blood transfusion.

         22. Patient is currently enrolled in another investigational device or drug trial that may
             influence the outcome of this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volkmar Falk, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Louis Vanoverschelde, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Saint-Luc, Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint- Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln Heart Center</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg- Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zurich - Klinik für Herzchirurgie, UniversitätsSpital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high risk</keyword>
  <keyword>surgical valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

